Literature DB >> 28040198

The biological and clinical significance of stromal-epithelial interactions in breast cancer.

Robert McCuaig1, Fan Wu1, Jenny Dunn1, Sudha Rao2, Jane E Dahlstrom3.   

Abstract

There is evidence that an aberrant tumour microenvironment (TME) facilitates cancer development, progression, and responses to treatment. While many of the mechanisms underlying the phenotype and cancer-promoting behaviour of the TME are unknown, epigenetic mechanisms in cancer cells and the TME are thought to play important roles. As a result, cancer profiling strategies for drug and biomarker development require a thorough understanding of both the epithelial tissue compartment and the TME. This review discusses recent advances in our understanding of how cancer epithelial cells interact with their microenvironment and how this knowledge can be exploited clinically.
Copyright © 2016 Royal College of Pathologists of Australasia. All rights reserved.

Entities:  

Keywords:  Breast cancer; DNA methylation; cancer associated fibroblasts; cancer stem cells; epi-drugs; epigenetics; histone; tumour microenvironment

Mesh:

Year:  2016        PMID: 28040198     DOI: 10.1016/j.pathol.2016.10.009

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  10 in total

Review 1.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

2.  The predictive value of inflammatory markers for pathological response of ipsilateral supraclavicular lymph nodes and for prognosis in breast cancer after neoadjuvant chemotherapy.

Authors:  Shaoqing Liu; Jing Fang; Dechuang Jiao; Zhenzhen Liu
Journal:  Gland Surg       Date:  2020-10

Review 3.  Lung carcinogenesis and fibrosis taken together: just coincidence?

Authors:  Ioanna Giopanou; Kristina A M Arendt; Georgios T Stathopoulos
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

4.  LSD1 activation promotes inducible EMT programs and modulates the tumour microenvironment in breast cancer.

Authors:  T Boulding; R D McCuaig; A Tan; K Hardy; F Wu; J Dunn; M Kalimutho; C R Sutton; J K Forwood; A G Bert; G J Goodall; L Malik; D Yip; J E Dahlstrom; A Zafar; K K Khanna; S Rao
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

Review 5.  Extracellular vesicle-mediated transport: Reprogramming a tumor microenvironment conducive with breast cancer progression and metastasis.

Authors:  Dara Brena; Ming-Bo Huang; Vincent Bond
Journal:  Transl Oncol       Date:  2021-11-25       Impact factor: 4.243

6.  Three-dimensional tumor model mimics stromal - breast cancer cells signaling.

Authors:  Stephanie Lemmo Ham; Pradip Shahi Thakuri; Madison Plaster; Jun Li; Kathryn E Luker; Gary D Luker; Hossein Tavana
Journal:  Oncotarget       Date:  2017-12-05

7.  Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.

Authors:  Mei Wu; Qi Sun; Chao-Hua Mo; Jin-Shu Pang; Jia-Yin Hou; Ling-Ling Pang; Hui-Ping Lu; Yi-Wu Dang; Su-Jie Fang; Deng Tang; Gang Chen; Zhen-Bo Feng
Journal:  Oncol Rep       Date:  2019-05-03       Impact factor: 3.906

Review 8.  Targeting cancer stem cell pathways for cancer therapy.

Authors:  Liqun Yang; Pengfei Shi; Gaichao Zhao; Jie Xu; Wen Peng; Jiayi Zhang; Guanghui Zhang; Xiaowen Wang; Zhen Dong; Fei Chen; Hongjuan Cui
Journal:  Signal Transduct Target Ther       Date:  2020-02-07

9.  Stromal desmoplasia as a possible prognostic indicator in different grades of oral squamous cell carcinoma.

Authors:  Heena Zainab; Ameena Sultana
Journal:  J Oral Maxillofac Pathol       Date:  2019 Sep-Dec

Review 10.  Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation.

Authors:  Tiansheng Li; Chao Mao; Xiang Wang; Ying Shi; Yongguang Tao
Journal:  J Exp Clin Cancer Res       Date:  2020-10-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.